genetically engineered autologous cancer cell vaccine (Morphogenesis)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Namegenetically engineered autologous cancer cell vaccine (Morphogenesis)
Drug Alias NameEMM55 antigen expressing autologous cancer cell vaccine (Morphogenesis)ImmuneFx autologous tumor cell vaccine (Morphogenesis)
ClassificationCell and gene therapy > Cell therapyVaccines > Application > Therapeutic vaccine
Mechanisms of ActionImmunomodulators
TargetsNot applicable
Therapy Area/IndicationsLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-CellNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesKintara Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesKintara Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-CellNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A